Back to today’s briefing

Story perspectives

BridgeBio's BBP-418 Shows Promise for LGMD2I FDA Approval

10/28/2025

30 4

Summary

Story summary

BridgeBio Pharma announced BBP-418 succeeded in Phase 3 trial for LGMD2I/R9, potentially paving the way for FDA approval.
The trial showed significant increases in a muscle-stabilizing protein and improvements in movement and lung function versus placebo.
BridgeBio plans to file for FDA approval in the first half of 2026.
Analysts expect BBP-418 to generate about $300 million in sales by 2030.

1 of 1

Story summary

BridgeBio Pharma announced BBP-418 succeeded in Phase 3 trial for LGMD2I/R9, potentially paving the way for FDA approval.
The trial showed significant increases in a muscle-stabilizing protein and improvements in movement and lung function versus placebo.
BridgeBio plans to file for FDA approval in the first half of 2026.
Analysts expect BBP-418 to generate about $300 million in sales by 2030.